JP2013523892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523892A5 JP2013523892A5 JP2013505098A JP2013505098A JP2013523892A5 JP 2013523892 A5 JP2013523892 A5 JP 2013523892A5 JP 2013505098 A JP2013505098 A JP 2013505098A JP 2013505098 A JP2013505098 A JP 2013505098A JP 2013523892 A5 JP2013523892 A5 JP 2013523892A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- retinal
- oil
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 206010046851 Uveitis Diseases 0.000 claims 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 150000003857 carboxamides Chemical class 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 229940124530 sulfonamide Drugs 0.000 claims 6
- 150000003456 sulfonamides Chemical class 0.000 claims 6
- 208000017442 Retinal disease Diseases 0.000 claims 5
- 201000004569 Blindness Diseases 0.000 claims 4
- 208000002367 Retinal Perforations Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 239000003921 oil Substances 0.000 claims 4
- 235000019198 oils Nutrition 0.000 claims 4
- 230000002207 retinal effect Effects 0.000 claims 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims 4
- 235000002639 sodium chloride Nutrition 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 239000003981 vehicle Substances 0.000 claims 4
- 208000029257 vision disease Diseases 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 208000002691 Choroiditis Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 208000003971 Posterior uveitis Diseases 0.000 claims 3
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 3
- 201000007737 Retinal degeneration Diseases 0.000 claims 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 3
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 3
- 206010047571 Visual impairment Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 3
- 210000001525 retina Anatomy 0.000 claims 3
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 230000004393 visual impairment Effects 0.000 claims 3
- 201000009487 Amblyopia Diseases 0.000 claims 2
- 206010005177 Blindness cortical Diseases 0.000 claims 2
- 208000014882 Carotid artery disease Diseases 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 235000019483 Peanut oil Nutrition 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 206010038897 Retinal tear Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims 2
- 208000013521 Visual disease Diseases 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 235000005687 corn oil Nutrition 0.000 claims 2
- 239000002285 corn oil Substances 0.000 claims 2
- 208000009153 cortical blindness Diseases 0.000 claims 2
- -1 cyano, thio Chemical group 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000001037 epileptic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- 239000000312 peanut oil Substances 0.000 claims 2
- 210000001927 retinal artery Anatomy 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 208000006379 syphilis Diseases 0.000 claims 2
- 210000000857 visual cortex Anatomy 0.000 claims 2
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 claims 1
- 235000019489 Almond oil Nutrition 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000007333 Brain Concussion Diseases 0.000 claims 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 240000000467 Carum carvi Species 0.000 claims 1
- 235000005747 Carum carvi Nutrition 0.000 claims 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010070957 Choroidal haemangioma Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 244000037364 Cinnamomum aromaticum Species 0.000 claims 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 208000021089 Coats disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 208000019878 Eales disease Diseases 0.000 claims 1
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 241000228402 Histoplasma Species 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010058558 Hypoperfusion Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 208000032578 Inherited retinal disease Diseases 0.000 claims 1
- 206010022557 Intermediate uveitis Diseases 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010064997 Necrotising retinitis Diseases 0.000 claims 1
- 206010065700 Ocular sarcoidosis Diseases 0.000 claims 1
- 208000034247 Pattern dystrophy Diseases 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 235000019484 Rapeseed oil Nutrition 0.000 claims 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 1
- 201000001949 Retinal Vasculitis Diseases 0.000 claims 1
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 1
- 208000032430 Retinal dystrophy Diseases 0.000 claims 1
- 206010038899 Retinal telangiectasia Diseases 0.000 claims 1
- 206010038915 Retinitis viral Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 235000019485 Safflower oil Nutrition 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 208000036038 Subretinal fibrosis Diseases 0.000 claims 1
- 235000019486 Sunflower oil Nutrition 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- 206010044269 Toxocariasis Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 239000008168 almond oil Substances 0.000 claims 1
- 229920006321 anionic cellulose Polymers 0.000 claims 1
- 239000010617 anise oil Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 210000002565 arteriole Anatomy 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 201000005849 central retinal artery occlusion Diseases 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 208000027129 choroid disease Diseases 0.000 claims 1
- 239000010630 cinnamon oil Substances 0.000 claims 1
- 239000010634 clove oil Substances 0.000 claims 1
- 230000009852 coagulant defect Effects 0.000 claims 1
- 201000008615 cone dystrophy Diseases 0.000 claims 1
- 208000006623 congenital stationary night blindness Diseases 0.000 claims 1
- 235000012343 cottonseed oil Nutrition 0.000 claims 1
- 239000002385 cottonseed oil Substances 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 229940124274 edetate disodium Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000010642 eucalyptus oil Substances 0.000 claims 1
- 229940044949 eucalyptus oil Drugs 0.000 claims 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 201000006321 fundus dystrophy Diseases 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- 239000000944 linseed oil Substances 0.000 claims 1
- 235000021388 linseed oil Nutrition 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 208000022766 lymph node neoplasm Diseases 0.000 claims 1
- 208000029233 macular holes Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000008940 ocular tuberculosis Diseases 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 208000008798 osteoma Diseases 0.000 claims 1
- XWCKCINXPIGGEB-UHFFFAOYSA-N oxadiazol-5-yl(piperidin-1-yl)methanone Chemical compound C=1N=NOC=1C(=O)N1CCCCC1 XWCKCINXPIGGEB-UHFFFAOYSA-N 0.000 claims 1
- 235000019477 peppermint oil Nutrition 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 201000004849 posterior scleritis Diseases 0.000 claims 1
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 210000000977 primary visual cortex Anatomy 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 239000000790 retinal pigment Substances 0.000 claims 1
- 239000010668 rosemary oil Substances 0.000 claims 1
- 229940058206 rosemary oil Drugs 0.000 claims 1
- 235000005713 safflower oil Nutrition 0.000 claims 1
- 239000003813 safflower oil Substances 0.000 claims 1
- 230000009919 sequestration Effects 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims 1
- 229940001474 sodium thiosulfate Drugs 0.000 claims 1
- 235000019345 sodium thiosulphate Nutrition 0.000 claims 1
- 239000003549 soybean oil Substances 0.000 claims 1
- 235000012424 soybean oil Nutrition 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000002600 sunflower oil Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000008181 tonicity modifier Substances 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 230000004304 visual acuity Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32463210P | 2010-04-15 | 2010-04-15 | |
| US61/324,632 | 2010-04-15 | ||
| PCT/US2011/032325 WO2011130411A1 (en) | 2010-04-15 | 2011-04-13 | Compositions and methods for treating visual disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523892A JP2013523892A (ja) | 2013-06-17 |
| JP2013523892A5 true JP2013523892A5 (enExample) | 2014-05-29 |
Family
ID=44009992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505098A Pending JP2013523892A (ja) | 2010-04-15 | 2011-04-13 | 視覚障害を処置するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110257186A1 (enExample) |
| EP (1) | EP2558100A1 (enExample) |
| JP (1) | JP2013523892A (enExample) |
| KR (1) | KR20130092976A (enExample) |
| AU (1) | AU2011239683A1 (enExample) |
| CA (1) | CA2796345A1 (enExample) |
| RU (1) | RU2012148214A (enExample) |
| WO (1) | WO2011130411A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201600127037A1 (it) * | 2016-12-15 | 2018-06-15 | Oftalab S R L | Soluzione oftalmica di verde di lissamina e suo uso in oftalmologia |
| CN109908327A (zh) * | 2019-03-12 | 2019-06-21 | 广州陈锦济生物科技有限公司 | 一种用于治疗近视的眼药水及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| WO2004062616A2 (en) * | 2003-01-13 | 2004-07-29 | Cortex Pharmaceuticals, Inc. | Method of treating cognitive decline due to sleep deprivation and stress |
| JP2009534415A (ja) * | 2006-04-20 | 2009-09-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ニューロトロフィン発現に対するａｍｐａ受容体モジュレーターの作用の薬理学的制御 |
| US20080139472A1 (en) * | 2006-10-06 | 2008-06-12 | The Regents Of The University Of California | Upregulating bdnf levels to mitigate mental retardation |
| AU2007342364A1 (en) | 2007-01-03 | 2008-07-17 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| PT2144506E (pt) * | 2007-01-03 | 2011-12-21 | Servier Lab | Composto de [1,2,3]-benzotriazinona substituída em posição 3 para aumentar as respostas glutamatérgicas nas sinapses |
| BRPI0815957A2 (pt) * | 2007-09-20 | 2019-09-24 | Cortex Pharma Inc | "composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas" |
-
2011
- 2011-04-12 US US13/085,241 patent/US20110257186A1/en not_active Abandoned
- 2011-04-13 EP EP11715842A patent/EP2558100A1/en not_active Withdrawn
- 2011-04-13 CA CA2796345A patent/CA2796345A1/en not_active Abandoned
- 2011-04-13 KR KR1020127029867A patent/KR20130092976A/ko not_active Withdrawn
- 2011-04-13 RU RU2012148214/15A patent/RU2012148214A/ru not_active Application Discontinuation
- 2011-04-13 WO PCT/US2011/032325 patent/WO2011130411A1/en not_active Ceased
- 2011-04-13 AU AU2011239683A patent/AU2011239683A1/en not_active Abandoned
- 2011-04-13 JP JP2013505098A patent/JP2013523892A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3045733C (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
| JP2019514956A5 (enExample) | ||
| JP2009511632A5 (enExample) | ||
| JP2018529693A5 (enExample) | ||
| RU2005118107A (ru) | Ингибиторы гистондеацетилазы для лечения офтальмологических неоваскулярных или отечных нарушений и заболеваний | |
| JP2011519360A5 (enExample) | ||
| JP2018536648A5 (enExample) | ||
| WO2016134223A3 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| JP2015523546A5 (enExample) | ||
| WO2012047966A3 (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| HRP20220138T1 (hr) | Peptidni pripravci i postupci uporabe | |
| JP2018514590A5 (enExample) | ||
| WO2020099925A3 (en) | Peptides and pharmaceutical compositions for treating eye diseases | |
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| RU2020118178A (ru) | Лекарственные средства и композиции для доставки в глаз | |
| RU2016104844A (ru) | Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| JP2017525758A5 (enExample) | ||
| HRP20190561T1 (hr) | Postupci liječenja bolesti oka povezanih s upalom i vaskularnom proliferacijom | |
| JP2010514733A5 (enExample) | ||
| JP2013523892A5 (enExample) | ||
| RU2009128968A (ru) | Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии | |
| RU2016151973A (ru) | Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами | |
| RU2020131402A (ru) | 4-метилдигидропиримидиноновые соединения и их применение в фармацевтике | |
| RU2012148214A (ru) | Композиции и способы для лечения нарушений зрения |